
Trump withdraws FDA commissioner nominee Heidi Overton, extending a leadership gap that leaves review and launch timelines uncertain for sponsors.
This case study is based on the experience of one of the authors but is applicable to all companies across the broader industry, illustrating the potentially surprising point that some compliance difficulties may be of the company’s own making.






